Cimzia (certolizumab pegol) is an antibody pharmaceutical. Certolizumab pegol was first approved as Cimzia on 2008-04-22. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tumor necrosis factor.
|Common Name||Certolizumab pegol|
|Indication||ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis|
|Drug Class||Monoclonal antibodies: humanized, immunomodulating; PEGylated compounds|